Jianwen Gao

Prof. Dr. Jianwen Gao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
ZWZehua Wang
Zehua Wang
JGJianwen Gao
Jianwen Gao
JZJiabing Zhou
Jiabing Zhou
HLHaiou Liu
Haiou Liu
CXCongjian Xu
Congjian Xu
Wang Z, et al. J Gynecol Oncol. 2018 Aug;30:e26. https://doi.org/10.3802/jgo.2019.30.e26

6 January 2020 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
ZWZehua Wang
Zehua Wang
JGJianwen Gao
Jianwen Gao
Yuko OhnoYuko Ohno
Yuko Ohno
HLHaiou Liu
Haiou Liu
CXCongjian Xu
Congjian Xu

1 July 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JGJianwen Gao
Jianwen Gao
ZWZehua Wang
Zehua Wang
JFJiayu Fu
Jiayu Fu
JAJisaihan A.
Jisaihan A.
Yuko OhnoYuko Ohno
Yuko Ohno
CXCongjian Xu
Congjian Xu
Ovarian cancer is the most lethal type of gynecological cancer. Due to its high heterogeneity and complicated pathological mechanisms, the 5‑year survival rate of patients with ovarian cancer is 1 than the other two combinations at all concentrations in A2780 and OVCAR‑3 cell lines. The difference in proliferation inhibition and induced apoptosis rate of A2780 cell lines was significant in the combination of cisplatin with olaparib group and the control group (P<0.01) at 0.25x IC50. For the OVCAR‑3 cell line, the difference was also significant between two groups (P<0.05). The CI values in the A2780 cell line revealed significant differences between the low‑dose group (0.0625x, 0.125x and 0.25x IC50) and the high‑dose group (0.5x, 1.0x and 2.0x IC50) for the group that received the combination of cisplatin with olaparib (P<0.05). The present study highlighted that the group receiving a combination of cisplatin with olaparib exhibited the most significant synergistic effects among the three combinations, particularly at low doses.

1 October 2024 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
WMWeiwei Miao
Weiwei Miao
ZWZhixiong Wang
Zhixiong Wang
JGJianwen Gao
Jianwen Gao
Yuko OhnoYuko Ohno
Yuko Ohno
Paridis Rhizoma saponins (PRS) are significant components of Rhizoma Paridis and have inhibitory effects on various tumors, such as bladder, breast, liver and colon cancer. Polyphyllin II (PPII), one of the PRS, has an unclear effect on breast cancer. The present study aimed to explore the effect and mechanism of PPII in breast cancer. A network pharmacology approach was employed to predict the core components and breast cancer‑related targets of PRS. Moreover, a xenograft tumor model was established to determine the anti‑breast cancer effect of PPII in vivo. The viability of MDA‑MB‑231 cells was determined by a Cell Counting Kit‑8 assay. Apoptosis was analyzed using annexin V/PI double staining. Additionally, Transwell and scratch assays were performed to evaluate invasion and migration. The potential mechanism was predicted by Kyoto Encyclopedia of Genes and Genomes enrichment analysis and molecular docking analysis and verified by western blot analysis. The effect of PPII on aerobic glycolysis in breast cancer cells was detected by lactic acid and pyruvate kits and Western blotting of glycolytic rate‑limiting enzymes. Network pharmacology analysis revealed 26 core targets involved in breast cancer and that PPII was the core active component of PRS. The in vivo studies showed that PPII could inhibit the growth of breast cancer in mice. In vitro experiments confirmed that PPII induced cancer cell apoptosis and inhibited invasion and migration. Furthermore, PPII was capable of suppressing the expression of key proteins in the PI3K/Akt signaling pathway, reducing the generation of aerobic glycolytic products, and diminishing the protein expression levels of hexokinase 2 and pyruvate kinase M2. The results indicated that PPII inhibited aerobic glycolysis in breast cancer cells through the PI3K/Akt signaling pathway, thereby inhibiting breast cancer growth.

21 June 2022 in Biogerontology
Verified
Journal Article
Closed access
PDF file
ZWZehua Wang
Zehua Wang
JGJianwen Gao
Jianwen Gao
CXCongjian Xu
Congjian Xu

25 June 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZWZehua Wang
Zehua Wang
JGJianwen Gao
Jianwen Gao
CXCongjian Xu
Congjian Xu
Metabolic disorders are considered the hallmarks of cancer and metabolic reprogramming is emerging as a new strategy for cancer treatment. Exogenous and endogenous stressors can induce cellular senescence; the interactions between cellular senescence and systemic metabolism are dynamic. Cellular senescence disrupts metabolic homeostasis in various tissues, which further promotes senescence, creating a vicious cycle facilitating tumor occurrence, recurrence, and altered outcomes of anticancer treatments. Therefore, the regulation of cellular senescence and related secretory phenotypes is considered a breakthrough in cancer therapy; moreover, proteins involved in the associated pathways are prospective therapeutic targets. Although studies on the association between cellular senescence and tumors have emerged in recent years, further elucidation of this complex correlation is required for comprehensive knowledge. In this paper, we review the research progress on the correlation between cell aging and metabolism, focusing on the strategies of targeting metabolism to modulate cellular senescence and the progress of relevant research in the context of anti-tumor therapy. Finally, we discuss the significance of improving the specificity and safety of anti-senescence drugs, which is a potential challenge in cancer therapy.